You just read:

MEI Pharma's Pracinostat Receives Breakthrough Therapy Designation from FDA for Treatment in Combination with Azacitidine of Patients with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Chemotherapy

News provided by

MEI Pharma, Inc.

01 Aug, 2016, 08:30 ET